{"id":"cggv:63312833-baef-4b11-9769-c93957decef6v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10110","date":"2022-09-02T16:00:00.000Z","role":"Approver"},{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10110","date":"2022-09-29T14:27:38.028Z","role":"Publisher"}],"evidence":[{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:32c1da76-a2ad-49ce-bf6e-4922c117c561","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:991c8230-64f6-42c5-9553-365f79458db2","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"GNS encodes N-acetylglucosamine-6-sulfatase (PMID: 3391615), an enzyme that is involved in the glycosaminoglycan degradation via catalyzing the hydrolysis of the 6-sulfate groups of the N-acetyl-D-glucosamine 6-sulfate moieties of heparan sulfate and keratan sulfate (PMID: 3689315). Among patients with MPS type IIID, deficient N-acetylglucosamine-6-sulfate sulfatase activity results in lysosomal accumulation of glycosaminoglycans in multiple tissues, leading to characteristic disease manifestations including CNS degeneration and skeletal dysostosis (PMID: 18392742). Thus, the biochemical function of the GNS gene (as a N-acetylglucosamine-6-sulfatase) is consistent with the disease process. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/3391615","type":"dc:BibliographicResource","dc:abstract":"Glucosamine-6-sulphatase (G6S), a lysosomal enzyme found in all cells, is involved in the catabolism of heparin, heparan sulphate, and keratan sulphate. Deficiency of G6S results in the accumulation of undegraded substrate and the lysosomal storage disorder mucopolysaccharidosis type IIID (Sanfilippo D syndrome). Regional mapping by in situ hybridization of a 3H-labelled human G6S cDNA probe to human metaphase chromosomes indicated that the G6S gene is localized to chromosome 12 at q14. The localization of the G6S gene to chromosome 12 was confirmed using the G6S cDNA clone in Southern blot hybridization analysis of DNA from human x mouse hybrid cell lines.","dc:creator":"Robertson DA","dc:date":"1988","dc:title":"Chromosomal localization of the gene for human glucosamine-6-sulphatase to 12q14."},"rdfs:label":"GNS encodes N-acetylglucosamine-6-sulfatase"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2,"dc:description":"Per ClinGen LD GCEP guidelines, gene products that have a well-established function in a metabolic pathway are scored 2 points"}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:9ad0f5c8-3b8f-403c-b8f9-a4daa0cbcd89","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:c21748d3-bfc0-443c-9ad5-00eddc5cdd09","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"GNS knockout mice treated with gene therapy showed recovery of N-acetylglucosamine-6-sulfatase enzyme activity activity to ~75% of wild-type levels and reduced lysosomal glycosaminoglycan accumulation in multiple tissues including brain and liver ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28334745","type":"dc:BibliographicResource","dc:abstract":"Gene therapy is a promising therapeutic alternative for Lysosomal Storage Disorders (LSD), as it is not necessary to correct the genetic defect in all cells of an organ to achieve therapeutically significant levels of enzyme in body fluids, from which non-transduced cells can uptake the protein correcting their enzymatic deficiency. Animal models are instrumental in the development of new treatments for LSD. Here we report the generation of the first mouse model of the LSD Muccopolysaccharidosis Type IIID (MPSIIID), also known as Sanfilippo syndrome type D. This autosomic recessive, heparan sulphate storage disease is caused by deficiency in N-acetylglucosamine 6-sulfatase (GNS). Mice deficient in GNS showed lysosomal storage pathology and loss of lysosomal homeostasis in the CNS and peripheral tissues, chronic widespread neuroinflammation, reduced locomotor and exploratory activity and shortened lifespan, a phenotype that closely resembled human MPSIIID. Moreover, treatment of the GNS-deficient animals with GNS-encoding adeno-associated viral (AAV) vectors of serotype 9 delivered to the cerebrospinal fluid completely corrected pathological storage, improved lysosomal functionality in the CNS and somatic tissues, resolved neuroinflammation, restored normal behaviour and extended lifespan of treated mice. Hence, this work represents the first step towards the development of a treatment for MPSIIID.","dc:creator":"Roca C","dc:date":"2017","dc:title":"Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID."},"rdfs:label":"Gene therapy in GNS knockout mouse"}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"cggv:56b337ad-6bf1-455a-bf8f-7062ca43faaa","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:882a7724-b06e-4cdf-97d4-4e31aebaa90f","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"GNS knockout mice show undetectable N-acetylglucosamine-6-sulfatase enzyme activity and CNS accumulation of glycosaminoglycans, recapitulating the human MPS IIID phenotype (PMID: 18392742, PMID: 9329460)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28334745","rdfs:label":"GNS knockout mouse"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:63312833-baef-4b11-9769-c93957decef6_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:1fafd930-9c4e-44ec-9b9e-8a1a227eee1b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:1fafd930-9c4e-44ec-9b9e-8a1a227eee1b","type":"Proband","allele":{"id":"cggv:7875607b-d5af-478e-a064-6c1c408c6f24","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002076.4(GNS):c.1168C>T (p.Gln390Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115885"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:3aabef79-f355-4a66-9edf-59b91455c1b7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7875607b-d5af-478e-a064-6c1c408c6f24"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17998446","type":"dc:BibliographicResource","dc:abstract":"Mucopolysaccharidosis type IIID (MPS-IIID), or Sanfilippo syndrome type D, is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetylglucosamine-6-sulfatase (GNS) gene, leading to impaired degradation of heparan sulfate.","dc:creator":"Jansen AC","dc:date":"2007","dc:title":"Sanfilippo syndrome type D: natural history and identification of 3 novel mutations in the GNS Gene."}},"rdfs:label":"Family 1: Patient 1"},{"id":"cggv:3aabef79-f355-4a66-9edf-59b91455c1b7","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3aabef79-f355-4a66-9edf-59b91455c1b7_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts to yield 1.5pts total and avoid double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:01357cc6-f55b-4a86-87ba-594abd3ff2a0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:01357cc6-f55b-4a86-87ba-594abd3ff2a0","type":"Proband","allele":{"id":"cggv:7f25da8f-be31-42a0-8ad6-fada578f9710","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002076.4(GNS):c.1169del (p.Gln390fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115884"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:ed720a5d-5147-4701-8686-741d56de9afd_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7f25da8f-be31-42a0-8ad6-fada578f9710"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12624138","type":"dc:BibliographicResource","dc:abstract":"Mucopolysaccharidosis type IIID is the least common of the four subtypes of Sanfilippo syndrome. It is caused by a deficiency of N-acetylglucosamine-6-sulphatase, which is one of the enzymes involved in the catabolism of heparan sulphate. We present the clinical, biochemical, and, for the first time, the molecular diagnosis of a patient with Sanfilippo D disease. The patient was found to be homozygous for a single base pair deletion (c1169delA), which will cause a frameshift and premature termination of the protein. Accurate carrier detection is now available for other members of this consanguineous family.","dc:creator":"Beesley CE","dc:date":"2003","dc:title":"Sanfilippo syndrome type D: identification of the first mutation in the N-acetylglucosamine-6-sulphatase gene."}},"rdfs:label":"Patient 1 - Beesley"},{"id":"cggv:ed720a5d-5147-4701-8686-741d56de9afd","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:ed720a5d-5147-4701-8686-741d56de9afd_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3b11a8c6-1dcb-4b3b-8483-46cea22f2fe1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3b11a8c6-1dcb-4b3b-8483-46cea22f2fe1","type":"Proband","allele":{"id":"cggv:8dd73cc9-6c4d-470c-898d-e6a7213ea345","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.64747877_64756599del (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573320250"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:2f70e343-3bb6-4a57-9597-5047cb934ea9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8dd73cc9-6c4d-470c-898d-e6a7213ea345"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16990043","type":"dc:BibliographicResource","dc:abstract":"Sanfilippo syndrome type D is an autosomal recessive lysosomal storage disease that is caused by a deficiency of N-acetylglucosamine-6-sulphatase, one of the enzymes involved in the catabolism of heparan sulphate. Only 15 patients have been described in the literature and just two mutations have been reported to date. We present the clinical, biochemical and molecular analysis of two Italian Sanfilippo D families. Novel homozygous mutations were identified in the affected patients from each family: a large intragenic deletion of 8723 bp encompassing exons 2 and 3 in family 1 and a nonsense mutation, Q272X, in family 2. The deletion is the first large intragenic deletion to be reported in any of the four Sanfilippo subtypes, including Sanfilippo type C in which the gene has recently been identified.","dc:creator":"Beesley CE","dc:date":"2007","dc:title":"Identification and characterisation of an 8.7 kb deletion and a novel nonsense mutation in two Italian families with Sanfilippo syndrome type D (mucopolysaccharidosis IIID)."}},"rdfs:label":"Patient 1 - Beesley 2007"},{"id":"cggv:2f70e343-3bb6-4a57-9597-5047cb934ea9","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:2f70e343-3bb6-4a57-9597-5047cb934ea9_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7f65a510-2649-40eb-a8d5-1adc2695ec89_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7f65a510-2649-40eb-a8d5-1adc2695ec89","type":"Proband","allele":{"id":"cggv:27f00d19-bc6a-49f2-a238-eb3c2087ddd7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.64721707T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA385602439"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:712fa469-eabe-42cc-be75-2a67e5982c5f_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:27f00d19-bc6a-49f2-a238-eb3c2087ddd7"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/20232353","type":"dc:BibliographicResource","dc:abstract":"Mucopolysaccharidosis III D (Sanfilippo disease type D, MPS IIID) is a rare autosomal recessive lysosomal storage disorder previously described in only 20 patients. MPS IIID is caused by a deficiency of N-acetylglucosamine-6-sulphate sulphatase (GNS), one of the enzymes required for the degradation of heparan sulphate. So far only seven mutations in the GNS gene have been reported. The clinical phenotype of 12 new MPS IIID patients from 10 families was studied. Mutation analysis of GNS was performed in 16 patients (14 index cases). Clinical signs and symptoms of the MPS IIID patients appeared to be similar to previously described patients with MPS III. Early development was normal with onset of behavioral problems around the age of 4 years, followed by developmental stagnation, deterioration of verbal communication and subsequent deterioration of motor functions. Sequence analysis of the coding regions of the gene encoding GNS (GNS) resulted in the identification of 15 novel mutations: 3 missense mutations, 1 nonsense mutation, 4 splice site mutations, 3 frame shift mutations, 3 large deletions and 1 in-frame small deletion. They include the first missense mutations and a relatively high proportion of large rearrangements, which warrants the inclusion of quantitative techniques in routine mutation screening of the GNS gene.","dc:creator":"Valstar MJ","dc:date":"2010","dc:title":"Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations."}},"rdfs:label":"Patient 10"},{"id":"cggv:712fa469-eabe-42cc-be75-2a67e5982c5f","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:712fa469-eabe-42cc-be75-2a67e5982c5f_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ec4f34cf-9594-4f75-9ec7-731d54a09632_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ec4f34cf-9594-4f75-9ec7-731d54a09632","type":"Proband","allele":{"id":"cggv:5b1fe9cd-c4df-498e-a706-cb27ba555fc1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002076.4(GNS):c.1138_1139insGTCCT (p.Asp380fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115887"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:3a2497c0-7fa7-4b7c-aa0d-6b714a6a4372_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5b1fe9cd-c4df-498e-a706-cb27ba555fc1"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17998446"},"rdfs:label":"Patient 4"},{"id":"cggv:3a2497c0-7fa7-4b7c-aa0d-6b714a6a4372","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3a2497c0-7fa7-4b7c-aa0d-6b714a6a4372_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:be4bb8e6-43dc-4374-bbaf-2903ad748054_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:be4bb8e6-43dc-4374-bbaf-2903ad748054","type":"Proband","allele":{"id":"cggv:f844d94f-86da-47c2-b533-abe733911eb4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002076.4(GNS):c.1063C>T (p.Arg355Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115882"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:6bca71a9-bdef-4048-a5fd-4e538965680c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f844d94f-86da-47c2-b533-abe733911eb4"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12573255","type":"dc:BibliographicResource","dc:abstract":"Mucopolysaccharidosis type IIID (MPS IIID; Sanfilippo syndrome type D; MIM 252940) is caused by deficiency of the activity of N-acetylglucosamine-6-sulfatase (GNS), which is normally required for degradation of heparan sulfate. The clinical features of MPS IIID include progressive neurodegeneration, with relatively mild somatic symptoms. Biochemical features include accumulation of heparan sulfate and N-acetylglucosamine-6-sulfate in the brain and viscera. To date, diagnosis required a specific lysosomal enzyme assay for GNS activity. From genomic DNA of a subject with MPS IIID, we amplified and sequenced the promoter and 14 exons of GNS. We found a homozygous nonsense mutation in exon 9 (1063C --> T), which predicted premature termination of translation (R355X). We also identified two common synonymous coding single-nucleotide polymorphisms and genotyped these in samples from four ethnic groups. This first report of a mutation in GNS resulting in MPS IIID indicates the potential utility of molecular diagnosis for this rare condition.","dc:creator":"Mok A","dc:date":"2003","dc:title":"Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase."}},"rdfs:label":"Patient 1 - Mok"},{"id":"cggv:6bca71a9-bdef-4048-a5fd-4e538965680c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:6bca71a9-bdef-4048-a5fd-4e538965680c_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and avoid double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ef953e3d-834e-4399-84d8-fe93fe51d218_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ef953e3d-834e-4399-84d8-fe93fe51d218","type":"Proband","allele":{"id":"cggv:e6edd2bb-b6ec-4ec8-af8a-6bf17054c752","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002076.4(GNS):c.1226dup (p.Ser410fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115888"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:4b35f2e8-e511-428f-a2de-059f132388e9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e6edd2bb-b6ec-4ec8-af8a-6bf17054c752"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19650410","type":"dc:BibliographicResource","dc:abstract":"A novel loss-of-function mutation in the GNS gene causes Sanfilippo syndrome type D: Mucopolysaccharidosis type IIID (MIM 252940) is the least common form of the four subtypes of Sanfilippo syndrome. It is an autosomal recessive lysosomal disorder caused by a deficiency of the N-acetylglucosamine-6-sulphatase (GlcNAc-6S sulphatase, GNS), a hydrolase, which is one of the enzymes involved in heparan sulfate catabolism leading to lysosomal storage. The clinical features of this disorder are progressive neurodegeneration with relatively mild somatic symptoms. Twenty patients have been described in the literature and only seven causative mutations in the GNS gene encoding GlcNAc-6S sulphatase have been reported to date. We present the clinical and molecular results of a newly diagnosed Turkish patient with MPS IIID. We identified the novel homozygous single base pair insertion, c.1226GinsG, which leads to a frame-shift and a premature truncation of the GNS protein (p.R409Rfs21X).","dc:creator":"ElÃ§ioglu NH","dc:date":"2009","dc:title":"A novel loss-of-function mutation in the GNS gene causes Sanfilippo syndrome type D."}},"rdfs:label":"Patient 1 - Elcioglu"},{"id":"cggv:4b35f2e8-e511-428f-a2de-059f132388e9","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:4b35f2e8-e511-428f-a2de-059f132388e9_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:56fc0f62-ac07-4824-8887-4f4e5130381c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:56fc0f62-ac07-4824-8887-4f4e5130381c","type":"Proband","allele":{"id":"cggv:d5cf2f8f-23e1-4aab-b4c3-6eb5e7e20360","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002076.4(GNS):c.814C>T (p.Gln272Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/638094"}},"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:d25d6e61-b11a-46f6-ab3d-849af6ffcb6d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d5cf2f8f-23e1-4aab-b4c3-6eb5e7e20360"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16990043"},"rdfs:label":"Patient 3 - Beesley 2007"},{"id":"cggv:d25d6e61-b11a-46f6-ab3d-849af6ffcb6d","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:d25d6e61-b11a-46f6-ab3d-849af6ffcb6d_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":5095,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"cggv:62f11052-4cd7-4ab5-b5bd-5c37c4d672ba","type":"GeneValidityProposition","disease":"obo:MONDO_0009658","gene":"hgnc:4422","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"The relationship between the GNS gene and mucopolysaccharidosis type IIID (MPS3D), an autosomal recessive lysosomal storage disorder, was evaluated using the ClinGen Clinical Validity Framework as of August 2, 2022. GNS encodes N-acetylglucosamine-6-sulfatase (PMID: 3391615), an enzyme that is involved in the glycosaminoglycan degradation via catalyzing the hydrolysis of the 6-sulfate groups of the N-acetyl-D-glucosamine 6-sulfate moieties of heparan sulfate and keratan sulfate (PMID: 3689315). Individuals with MPS3D show impaired N-acetylglucosamine-6-sulfate sulfatase activity, resulting in lysosomal accumulation of glycosaminoglycans in multiple tissues, which leads to characteristic disease manifestations including CNS degeneration and skeletal dysostosis (PMID: 18392742). \n\nThe disease mechanism of MPS3D is loss of function. MPS3D was first reported in 1980 by Kresse et al. (PMID: 6450420) and the first reports of biallelic variants in GNS among MPS3D cases in 2003 by Mok et al. (PMID: 12573255) and Beasley et al. (PMID: 12624138). Both case-level (genetic) and experimental evidence support the relationship between GNS and MPS3D. Reported causal variants include missense, nonsense, frameshift, and splice-altering variants (PMID: 12573255, PMID: 12624138, PMID: 17998446, PMID: 17998446, PMID: 19650410, PMID: 16990043, PMID: 16990043, PMID: 20232353). In total, eight variants from eight probands in eight publications were curated. Although there is additional published case-level evidence available, the maximum score for genetic evidence (12 points) has already been reached. \n\nExperimental evidence for the relationship between GNS and MPS3D includes: the biochemical function of the gene product (N-acetylglucosamine-6-sulfatase) being consistent with the clinical and biochemical findings identified individuals with MPS3D (PMID: 18392742); the biochemical and clinical features of GNS knockout mice (PMID: 28334745); and rescue of enzyme function via gene therapy in GNS knockout mice (PMID: 28334745). Additional experimental evidence is available, but the maximum score for experimental evidence (6 points) has already been reached.\n\nIn sum, GNS is definitively associated with MPS3D. The association has been repeatedly demonstrated in both clinical and research settings, and has been upheld over time. This clinical validity classification was approved by the ClinGen Lysosomal Diseases GCEP on September 2, 2022 (SOP v9).","dc:isVersionOf":{"id":"cggv:63312833-baef-4b11-9769-c93957decef6"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}